Enveric Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $5.54M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | During market hours | – | $0.76 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 15, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 27, 2026 | During market hours | – | $-6.12 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | During market hours | – | $-10.81 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | – | $-0.97 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | During market hours | – | $1.22 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | – | $-4.83 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | During market hours | – | $-0.24 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 26, 2024 | Before market open | – | – | – |
Press releases
Announcements Enveric Biosciences filed with the SEC
Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Biosciences Reports Financial Results and Provides Corporate Update for
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Reports Third Quarter 2025 Financial and Corporate Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Announces Reverse Stock Split
Listing notice · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Biosciences Relocates Corporate Headquarters to Cambridge, MA
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Reports Second Quarter 2025 Financial and Corporate Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Reports First Quarter 2025 Financial and Corporate Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Announces Pricing of $5 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Biosciences Announces Closing of $5 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Reports Third Quarter 2024 Financial and Corporate Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Reports Second Quarter 2024 Financial and Corporate Results
Results of operations · EX-99.1 to Form 8-K
Science & Technology and Enveric Biosciences Announce Licensing Agreement
Material agreement · Other events · EX-99.1 to Form 8-K
Biosciences Reports First Quarter 2024 Financial and Corporate Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
Results of operations · EX-99.1 to Form 8-K
Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Reports Third Quarter 2023 Corporate and Financial Results
Results of operations · EX-99.1 to Form 8-K
Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences to Present at the Centurion One 5 th Global Summit
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Announces Two Poster Presentations at the 6 th Neuropsychiatric Drug Development Summit
Regulation FD disclosure · EX-99.1 to Form 8-K
Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates
Regulation FD disclosure · EX-99.1 to Form 8-K